Severity of histological damage was graded according to the strength of inflammatory Torin 1 research buy cell infiltration and liver cellular necrosis. TNF-α and INF-γ levels in supernatant fluid released from

lymphocytes of the spleens were also measured. Results: Results: The EAIHs induced by peak II protein plus CFA and S100 plus CFA had significantly higher histological grades (2.8 and 2.6 on average) than those induced by peak I proteins plus CFA and peak III proteins plus CFA or by CFA alone and saline alone (2.2, 1.6, 1.0 and 0.2 respectively) (p < 0.05). T-cell reactivity increased after the stimulation with hapten peak I protein as compared with those of other groups. TNF-α and INF-γ levels in supernatant fluid from the lymphocytes of the spleens were increased significantly with the development of EAIH (p < 0.05). Conclusion: Conclusion:

Syngeneic hapten protein S100, and its three check details separated peak proteins had different immunopathological potentials on the pathogenesis of EAIH with peak II protein being more liver-specific than the others. Key Word(s): 1. liver; 2. antoimmune; 3. autoantigen; Presenting Author: WEIMIN XU Corresponding Author: WEIMIN XU Affiliations: Gastroenteroiogy Objective: To investigate the clinical value of detection of autoantibodies in 103 patients with elevated liver enzymes. Methods: three group patients (103 patients with elevated liver enzymes,85 patients with chronic hepatitis B, 80 healthy subjects) were examined for autoantibodies respectively. Antinuclear antibody (ANA), antimitochondrial antibody (AMA) and anti-smooth muscle antibody (SMA) were tested by indrect immunofluorescence; Antibodies to soluble liver antigen/liver

pancreas (SLA/LP), liver kidney microsomal type 1(LKM-1), liver cytosol type 1(LC-1) and mitochondrial type II (AMA-M2) were tested by Western blot. Results: Among 103 patients with elevated liver enzymes, LKM-1 was positive in 2 patients and SLA/LP in 1 patient and AMA-M2 in 3 patients. The positive rates of ANA, AMA, SMA in chronic hepatitis B group were 12.9%, 1.1%, 2.3% respectively; that in patients with elevated liver enzymes group were 34.9%, 8.7%, 12.6% respectively; that Sorafenib supplier in control group were 5.0%, 0, 0 respectively. The positive rates of ANA, AMA, SMA in chronic hepatitis B group and in patients with elevated liver enzymes group were significantly increased as compared with those of control group (p < 0.05). 6 patients with primary biliary cirrhosis (PBC) and 4 patients with autoimmune hepatitis (AIH) were diagnosed in 103 patients with elevated liver enzymes. Conclusion: The autoantibodies detection in patients with elevated liver enzymes has an important significance in clinical diagnosis.